BIOA
BioAge Labs, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.59
+0.95%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.3x
Market Cap
$440.15M
MomentumView details →
1D Return
+0.95%
YTD Return
−27.78%
RSI (14)
34.1
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.3x
Market Cap
$440.15M
RSI (14)
34.1
MomentumView details →
1D Return
+0.95%
YTD Return
−27.78%
SummaryUpdated Jun 1, 2026
BioAge Labs, Inc. (NASDAQ:BIOA) is a clinical-stage biopharmaceutical company founded in 2015 and based in Richmond, California. The company went public in September 2024, marking its transition from a private research entity to a publicly traded biotechnology firm. BioAge specializes in developing therapeutic treatments for metabolic diseases by leveraging insights into the molecular mechanisms of aging. The company's approach centers on understanding how aging processes contribute to various health conditions, particularly focusing on obesity and neuroinflammation-related disorders.
Similar companies
Latest newsMore news →
Dimensional Fund Advisors LP acquired a new position of 214,546 shares in BioAge Labs, Inc. during the first quarter, valued at approximately $3,746,000, as disclosed in its Form 13F filing.23d agoBioAge Labs, Inc. reported a second-quarter loss of $0.58 per share, beating the Zacks Consensus Estimate of a loss of $0.65 and improving from a loss of $0.60 per share a year earlier.30d ago